We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Alligator Bioscience AB (ATORX) NPV

Sell:1.01 SEK Buy:1.02 SEK Change: 0.022 SEK (2.12%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:1.01 SEK
Buy:1.02 SEK
Change: 0.022 SEK (2.12%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:1.01 SEK
Buy:1.02 SEK
Change: 0.022 SEK (2.12%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.

Contact details

Address:
SCHEELEVAGEN 2 byggnad 401
LUND
22363
Sweden
Telephone:
+46 (46) 5408200
Website:
https://alligatorbioscience.se/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ATORX
ISIN:
SE0000767188
Market cap:
830.90 million SEK
Shares in issue:
658.90 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Soren Bregenholt
    Chief Executive Officer
  • Marie Svensson
    Chief Financial Officer
  • Laura Von Schantz
    Chief Technology Officer
  • Sumeet Ambarkhane
    Chief Marketing Officer
  • Peter Ellmark
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.